Most-Downgraded StocksMost-DowngradedNASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $140.60 -0.95 (-0.67%) Closing price 04:00 PM EasternExtended Trading$140.64 +0.04 (+0.03%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Insulet Stock (NASDAQ:PODD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Insulet alerts:Sign Up Key Stats Today's Range$139.96▼$142.1750-Day Range$131.96▼$170.6252-Week Range$126.40▼$354.88Volume2.51 million shsAverage Volume1.37 million shsMarket Capitalization$9.75 billionP/E Ratio26.28Dividend YieldN/APrice Target$195.40Consensus RatingHold Company Overview Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps. The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies. The Omnipod 5 Automated Insulin Delivery System is designed to communicate with compatible continuous glucose monitoring systems and automatically adjust insulin delivery through the company’s SmartAdjust technology. Insulet also offers the Omnipod DASH system and other products serving different insulin-delivery needs. Founded in 2000, Insulet serves customers through direct operations and commercial partners in the United States and select international markets, including Canada, Europe and Australia. The company is headquartered in Acton, Massachusetts. Jim Hollingshead has served as Insulet’s president and chief executive officer since 2022.AI Generated. May Contain Errors. Read More Insulet Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScorePODD MarketRank™: Insulet scored higher than 81% of companies evaluated by MarketBeat, and ranked 99th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingInsulet has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on no strong buy ratings, 13 buy ratings, 11 hold ratings, and 2 sell ratings.Upside PotentialInsulet has a consensus price target of $195.40, representing about 39.0% upside from its current price of $140.60.Amount of Analyst CoverageInsulet has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.28% Earnings GrowthEarnings for Insulet are expected to grow by 18.28% in the coming year, from $6.51 to $7.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 26.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 26.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.66.Price to Earnings Growth RatioInsulet has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.44% of the float of Insulet has been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 2.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 20.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.03 News SentimentInsulet has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Insulet this week, compared to 10 articles on an average week.Search InterestOnly 13 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have not sold or bought any company stock.Percentage Held by Insiders0.36% of the stock of Insulet is held by insiders.Percentage Held by InstitutionsInsulet has minimal institutional ownership at this time.Read more about Insulet's insider trading history. Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PODD Stock News HeadlinesInsulet Introduces New Executive Deferred Compensation Plan3 hours ago | theglobeandmail.comInsulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare ForumSeptember 18 at 8:00 AM | businesswire.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.September 18 at 1:00 AM | Porter & Company (Ad)2 S&P 500 stocks with impressive fundamentals and 1 we turn downSeptember 14, 2026 | msn.comInsulet Corp. stock underperforms Thursday when compared to competitorsSeptember 11, 2026 | marketwatch.comInsulet announces upcoming director resignations amid transitionsSeptember 10, 2026 | tipranks.comInsulet Corporation (NASDAQ:PODD) Receives $195.40 Average PT from BrokeragesSeptember 10, 2026 | americanbankingnews.comInsulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comSee More Headlines PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $284.24 at the start of the year. Since then, PODD stock has decreased by 50.5% and is now trading at $140.60. How were Insulet's earnings last quarter? Insulet Corporation (NASDAQ:PODD) posted its earnings results on Wednesday, August, 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. The company's revenue was up 23.5% on a year-over-year basis. Read the conference call transcript. Who are Insulet's major shareholders? Top institutional investors of Insulet include BlackRock Inc. (9.66%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.12%), Man Group plc (0.75%) and Amundi (0.73%). Insiders that own company stock include Timothy J Scannell, John W Kapples, Michael R Minogue, Mark N Field, Eric Benjamin, Timothy C Stonesifer, Lauren Budden, Laetitia Cousin, Prem Singh, Wayne AI Frederick and Shacey Petrovic. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC). Company Calendar Last Earnings8/05/2026Today9/18/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PODD's financial health is in the Red zone, according to TradeSmith. PODD has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PODD CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees5,400Year Founded2000Price Target and Rating Average Price Target for Insulet$195.40 High Price Target$375.00 Low Price Target$144.00 Potential Upside/Downside+39.0%Consensus RatingHold Rating Score (0-4)2.42 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$5.35 Trailing P/E Ratio26.28 Forward P/E Ratio21.60 P/E Growth1.11Net Income$247.10 million Net Margins12.29% Pretax Margin16.20% Return on Equity29.29% Return on Assets13.31% Debt Debt-to-Equity Ratio0.65 Current Ratio2.48 Quick Ratio1.83 Sales & Book Value Annual Sales$3.05 billion Price / Sales3.19 Cash Flow$6.32 per share Price / Cash Flow22.24 Book Value$21.54 per share Price / Book6.53Miscellaneous Outstanding Shares69,354,000Free Float69,104,000Market Cap$9.75 billion OptionableOptionable Beta1.08 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PODD) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
